Paper21098518
Current trends in the structure-activity relationships of sialyltransferases.
Audry M and 5 others. Glycobiology, 2011. Cited by 137 papers, by iCite.
Cite this record
ConductScience Library. Current trends in the structure-activity relationships of sialyltransferases. Papers, record 21098518. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21098518
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sialyltransferases | Major topic |
| Animals | |
| Biocatalysis | |
| Humans | |
| Models, Molecular | |
| N-Acetylneuraminic Acid | |
| Protein Folding | |
| Structure-Activity Relationship |
Source PubMed
Cited by83
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 137 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41724788 | Bacterial post-translational changes: the possible enigma of multidrug resistance. | Arch Microbiol | 2026 | https://conductscience.org/library/papers/41724788 | PubMed |
| 41142343 | A Potent Oral Sialylation Inhibitor Augments the Immunotherapy in Pancreatic Ductal Adenocarcinoma. | ACS Cent Sci | 2025 | https://conductscience.org/library/papers/41142343 | PubMed |
| 41004058 | Reactive Microglia and Astrocytes as Therapeutic Targets in Prion Diseases. | Subcell Biochem | 2025 | https://conductscience.org/library/papers/41004058 | PubMed |
| 40852041 | Glycosylation in kidney diseases. | Precis Clin Med | 2025 | https://conductscience.org/library/papers/40852041 | PubMed |
| 40649198 | The Role of Glycans in Human Immunity-A Sweet Code. | Molecules | 2025 | https://conductscience.org/library/papers/40649198 | PubMed |
| 40377806 | Sialyltransferase gene signature as a predictor of prognosis and therapeutic response in kidney renal clear cell carcinoma. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40377806 | PubMed |
| 40309065 | Synthesis of 4-azido sialic acid for testing against Siglec-7 and in metabolic oligosaccharide engineering. | RSC Chem Biol | 2025 | https://conductscience.org/library/papers/40309065 | PubMed |
| 40244513 | Aberrant Sialylation in Ovarian Cancer: Orchestrating Progression, Metastasis, and Therapeutic Hurdles. | Curr Med Sci | 2025 | https://conductscience.org/library/papers/40244513 | PubMed |
| 39858526 | Developmental and Epileptic Encephalopathy: Pathogenesis of Intellectual Disability Beyond Channelopathies. | Biomolecules | 2025 | https://conductscience.org/library/papers/39858526 | PubMed |
| 39596031 | Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39596031 | PubMed |
| 39524749 | Construction and experimental verification of a novel nine-glycosylation-related gene prognostic risk model for clear cell renal carcinoma. | Heliyon | 2024 | https://conductscience.org/library/papers/39524749 | PubMed |
| 37247156 | The vertebrate sialylation machinery: structure-function and molecular evolution of GT-29 sialyltransferases. | Glycoconj J | 2023 | https://conductscience.org/library/papers/37247156 | PubMed |
| 36873089 | Compound heterozygous variants within two conserved sialyltransferase motifs of ST3GAL5 cause GM3 synthase deficiency. | JIMD Rep | 2023 | https://conductscience.org/library/papers/36873089 | PubMed |
| 36452458 | Deficiency in ST6GAL1, one of the two α2,6-sialyltransferases, has only a minor effect on the pathogenesis of prion disease. | Front Mol Biosci | 2022 | https://conductscience.org/library/papers/36452458 | PubMed |
| 36338080 | Biological functions of sialic acid as a component of bacterial endotoxin. | Front Microbiol | 2022 | https://conductscience.org/library/papers/36338080 | PubMed |
| 36029403 | Aberrant Protein Glycosylation in Brain Cancers, with Emphasis on Glioblastoma. | Adv Exp Med Biol | 2022 | https://conductscience.org/library/papers/36029403 | PubMed |
| 36010674 | Glycosylation in Renal Cell Carcinoma: Mechanisms and Clinical Implications. | Cells | 2022 | https://conductscience.org/library/papers/36010674 | PubMed |
| 34842612 | Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors. | Antibodies (Basel) | 2021 | https://conductscience.org/library/papers/34842612 | PubMed |
| 34778769 | Synthesis and biological evaluation of selective phosphonate-bearing 1,2,3-triazole-linked sialyltransferase inhibitors. | RSC Med Chem | 2021 | https://conductscience.org/library/papers/34778769 | PubMed |
| 34650588 | Haploinsufficiency of the Attention-Deficit/Hyperactivity Disorder Risk Gene St3gal3 in Mice Causes Alterations in Cognition and Expression of Genes Involved in Myelination and Sialylation. | Front Genet | 2021 | https://conductscience.org/library/papers/34650588 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABO | 28 | PubTator's text mining | https://conductscience.org/library/genes/28 | NCBI Gene |
| ITGA2B | 3674 | PubTator's text mining | https://conductscience.org/library/genes/3674 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21098518
GET https://conductscience.org/api/papers/v1/21098518/cited_by?page=2